Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks

Lasers in Surgery and Medicine

Volumn 40, Issue 9, 2008, Pages 605-610

  Chang, Cheng Jen ^a   Hsiao, Yen Chang ^a   Mihm Jr , Martin C ^b   Nelson, J Stuart ^c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Port wine stain; Pulsed dye laser

Indexed keywords

HEMOGLOBIN; IMIQUIMOD;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; INTERMETHOD COMPARISON; MALE; NEVUS FLAMMEUS; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; PULSED DYE LASER; QUANTITATIVE ANALYSIS; REVASCULARIZATION; SCORING SYSTEM; SPECTROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AMINOQUINOLINES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERON INDUCERS; LASER THERAPY; LASERS, DYE; MALE; MIDDLE AGED; PILOT PROJECTS; PORT-WINE STAIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55449131051     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.20716     Document Type: Article

References (26)

1. Mulliken JB, Young AR. Vascular Birthmarks-Hemangiomas and malformations. Philadelphia: WB Saunders; 1988.
2. Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics 1976;58:218-222.
3. Pratt AG. Birthmarks in infants. Arch Dermatol Syphilol 1953;67:302-305.
4. Kalick SM. Toward an interdisciplinary psychology of appearances. Psychiatry 1978;41:249-254.
5. Heller A, Rafman S, Svagulis I, Pless IB. Birth defects and psychosocial adjustment. Am J Dis Child 1985;139:257-263.
6. Malm M, Calber NN. Port-wine stain - A surgical and psychological problem. Ann Plast Surg 1988;20:512-516.
7. Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991;17:76-79.
8. Barsky SH, Rosen S, Geer DE, Noe JM. The nature and evolution of port wine stains: A computer assisted study. J Invest Dermatol 1980;74:154-157.
9. Renfro L, Geronemus RG. Anatomical differences in the treatment of port wine stains with the pulsed dye laser. Arch Dermatol 1993;29:182-188.
10. Geronemus R, Lou W, Quintana A, Kauvar A. High fluence modified pulsed dye laser photocoagulation with dynamic cooling for port wine stains in infancy. Arch Dermatol 2000;136:942-943.
11. van der Horst CMAM, Koster PHL, deBorgie CAJM, Bossuyt PMM, van Gemert MJC. Effect of timing of treatment of port-wine stains with the flash-lamp-pumped pulsed dye laser. N Engl J Med 1998;338:1028-1033.
12. Morelli JG, Weston WL, Huff JC, Yohn JJ. Initial lesion size as a predictive factor in determining the response of port-wine stains in children treated with the pulsed dye laser. Arch Pediatr Adolesc Med 1995;149:1142-1144.
13. Lanigan SW. Port-wine stains unresponsive to pulsed dye laser: Explanations and solutions. Brit J Dermatol 1998;139:173-177.
14. Mork NJ, Austad J, Helsing P. Do port wine stains recur after successful treatment with pulsed dye laser? J Eur Acad Dermatol Venereol 1998;11:S142-S143.
15. Huikeshoven M, Koster PHL, de Borgie CAJM, Beek J, van Gemert MJC, van der Horst CMAM. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med 2007;356:1235-1240.
16. Phung TL, Oble DA, Jia W, Benjamin LE, Mihm MC, Nelson JS. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Lasers Surg Med 2008;40:1-5.
17. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-974.
18. Kouba DJ, Yip D, Fincher EF, Moy RL. Topical imiquimod in the treatment of a long-standing capillary malformation. Br J Dermatol 2007;157(5):1071-1072.
19. Sun ZJ, Zhao YF, Zhang WF. Immune response: A possible role in the pathophysiology of hemangioma. Med Hypotheses 2007;68(2):353-355.
20. Ho NT, Lansang P, Pope E. Topical iniquimod in the treatment of infantile hemangiomas: A retrospective study. J Am Acad Dermatol 2007;56(1):63-68.
21. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-S11.
22. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol 2002;47(4):571-577.
23. Sullivan TP, Dearaujo T, Vincek V, Berman B. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 2003;29(12):1181-1186.
24. Serrao VV, Paris FR, Feio AB. Genital vitiligo-like depigmentation following use of imiquimod 5% cream. Eur J Dermatol 2008;8(3):342-343.
25. Tejasvi T, Sharma VK, Kaur J. Determination of minimal erythemal dose for narrowband-ultraviolet B radiation in north Indian patients: Comparison of visual and Dermaspectrometer readings. Indian J Dermatol Venereol Leprol 2007; 73(2):97-99.
26. Ramsing DW, Agner T. Effect of glove occlusion on human skin. (I). Short-term experimental exposure. Contact Dermatitis 1996;34(1):1-5.